Johnson & Johnson (JNJ)
J&J Q2 Earnings Beat on Darzalex, Tremfya Growth, 2026 Outlook Raised
JNJ tops Q2 earnings and sales estimates, driven by key drug growth, and raises its 2026 outlook despite a slight MedTech sales miss.
Johnson & Johnson Q2: Solid (If Not Spectacular) Performance Satisfies Wall Street
Johnson & Johnson delivered strong Q2 2026 results, with 6.6% annual revenue growth and robust performance across Pharma and MedTech divisions. JNJ maintains mid-to-high single digit revenue growth, a portfolio of 15+ "blockbuster" drugs, and a solid pipeline, supporting its blue-chip status. I am downgrading JNJ from Strong Buy to Buy due to valuation normalization and tempered forward share price expectations, despite continued operational strength.
Johnson & Johnson beats Q2 estimates, raises full-year 2026 guidance
Johnson & Johnson (NYSE:JNJ) reported better-than-expected second quarter results and raised its full-year 2026 outlook, as strong pharmaceutical sales helped offset headwinds from products facing patent competition. The healthcare company posted adjusted earnings per share of $2.90 for the quarter, ahead of the Wall Street consensus estimate of $2.85.
JNJ Struggles for Direction Despite Notable Q2 Beat
Johnson & Johnson (NYSE:JNJ) is up 0.5% at $255.03 this morning, attempting to pivot higher and shed its early pre-market losses.
Johnson & Johnson (JNJ) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates
While the top- and bottom-line numbers for Johnson & Johnson (JNJ) give a sense of how the business performed in the quarter ended June 2026, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Johnson & Johnson Q2 Earnings Call Highlights
Johnson & Johnson NYSE: JNJ raised its full-year 2026 outlook after reporting second-quarter sales growth that management said was supported by strength in Innovative Medicine, new product launches and a broad portfolio that helped offset continued pressure from STELARA biosimilar competition.
Johnson & Johnson (JNJ) Q2 Earnings and Revenues Top Estimates
Johnson & Johnson (JNJ) came out with quarterly earnings of $2.9 per share, beating the Zacks Consensus Estimate of $2.84 per share. This compares to earnings of $2.77 per share a year ago.
FTSE 100 Live: Miners drag on China slowdown, PayPal jumps on bid
FTSE 100 down 23 points to 10,506 Miners fall on weaker China GDP Barratt Redrow, ICG, B&M, NextEnergy Solar publish updates 12.13pm: European stocks in...
Healthcare ETFs to Buy as JNJ Beats the Market With a 25% YTD Surge
JNJ's 25% year-to-date surge and recent FDA approval fuel interest in healthcare ETFs with diversified sector exposure.
Is Johnson & Johnson Stock Poised for New Highs as Q2 Results Approach?
After hitting fresh all-time highs last week, investors are turning their attention to JNJ's Q2 report, which is scheduled for Wednesday, July 15, before the opening bell.
JNJ Vs. KO: Which Dividend Stock Is The Better Buy?
Johnson & Johnson (NYSE:JNJ | JNJ Price Prediction) and Coca-Cola (NYSE:KO) both delivered Q1 2026 beats and both are being crowded into by capital rotating out of tech.
Is JNJ Stock a Buy, Sell or Hold Ahead of Q2 Earnings Release?
JNJ is set to report second-quarter results on July 15 as investors weigh strong growth drivers, new launches and patent headwinds shaping its long-term outlook.
